Loading…
Beta Bionics, Inc. is projected to rise to $19.79 by 2027, a +54% move from its current price of $12.83. BBNX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $12.37 | $12.85 | $13.34 | +0.12% |
| Aug 3 | $12.19 | $12.86 | $13.57 | +0.24% |
| Aug 4 | $12.06 | $12.88 | $13.75 | +0.36% |
| Aug 5 | $11.95 | $12.89 | $13.91 | +0.48% |
| Aug 6 | $11.86 | $12.91 | $14.05 | +0.60% |
| Aug 7 | $11.78 | $12.92 | $14.18 | +0.72% |
| Aug 8 | $11.71 | $12.94 | $14.30 | +0.84% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.71 | $12.94 | $14.30 | +0.84% |
| Week 2 | $11.32 | $13.05 | $15.03 | +1.69% |
| Week 3 | $11.06 | $13.16 | $15.65 | +2.55% |
| Week 4 | $10.86 | $13.27 | $16.21 | +3.41% |
| Week 5 | $10.69 | $13.38 | $16.74 | +4.28% |
| Week 6 | $10.56 | $13.49 | $17.24 | +5.16% |
| Week 7 | $10.44 | $13.61 | $17.73 | +6.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Beta Bionics, Inc. is a commercial-stage medical device company focused on insulin delivery solutions for diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
The company is developing Patch Pump, a skin-adhering insulin pump, and Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It was incorporated in 2015 and is headquartered in Irvine, California.
Beta Bionics has collaboration and license agreements with Xeris Pharmaceuticals, Inc. to develop and commercialize a pump-compatible glucagon formulation, and with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system.
BBNX is trading at $12.83 with a market cap of $577.22M, and it ranks 2793. The current price sits in a 30-day range of $10.00 to $16.47, with near-term technical levels guiding activity.
The SMA50 is $14.79 and the SMA200 is $17.57, with support at $12.83 and resistance at $17.82. The price picture sits near a defined support area, with a ceiling near the stated resistance level.
Forecast data imply a bullish trajectory over the coming years, with 2026 showing an average of $12.83 and higher annual averages thereafter: 2027 $19.79, 2028 $22.23, 2029 $23.26, 2030 $24.27, 2031 $25.64, 2032 $27.51, 2033 $35.96, 2034 $41.17, 2035 $42.41, 2040 $61.85, and 2050 $109.98. These figures accompany rising sentiment in the forecast and illustrate a path toward substantial upside.
A major floor 30.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 38.9% above — a clean break opens room to run.
A major ceiling 51.9% above — clearing it would confirm fresh momentum.
Key BBNX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BBNX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $14.81 | Sell | $14.47 | Sell |
| MA 10 | $15.78 | Sell | $15.27 | Sell |
| MA 20 | $16.30 | Sell | $15.66 | Sell |
| MA 50 | $14.79 | Sell | $14.89 | Sell |
| MA 100 | $12.69 | Buy | $14.64 | Sell |
| MA 200 | $17.57 | Sell | $15.81 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 29.54 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -282.71 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.54 | Sell |
| ROC (12) | -23.90 | Sell |
| Bollinger %B (20,2) | -0.27 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.41 | Buy |
| Awesome (5,34) | -0.98 | Sell |
| Ultimate (7,14,28) | 13.80 | Buy |
| Momentum (10) | -4.46 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 13.89 | Sell |
| ADX (14) | 23.14 | Sell |
| ATR (14) | 0.51 | Info |
The 30-day technical picture shows a neutral stance with RSI14 at 30, indicating potential oversold conditions.
The stock is trading near support at $12.83, while the 50-day moving average sits at $14.79 and the 200-day moving average at $17.57. The 30-day range runs from $10.00 to $16.47, illustrating recent price volatility within a defined band.
Overall, near-term dynamics point to a careful watch of support near $12.83 and resistance near $17.82, with volatility reflected in the 70% annualized volatility figure.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.86 | $12.83 | $20.87 | 0% | Neutral | |
| $15.23 | $19.79 | $27.50 | +54% | Bullish | |
| $16.42 | $22.23 | $32.46 | +73% | Bullish | |
| $16.61 | $23.26 | $35.28 | +81% | Bullish | |
| $16.81 | $24.27 | $37.99 | +89% | Bullish | |
| $17.27 | $25.64 | $41.25 | +100% | Bullish | |
| $18.05 | $27.51 | $45.36 | +114% | Bullish | |
| $23.02 | $35.96 | $60.61 | +180% | Bullish | |
| $25.74 | $41.17 | $70.81 | +221% | Bullish | |
| $25.91 | $42.41 | $74.30 | +231% | Bullish | |
| $33.99 | $61.85 | $117.06 | +382% | Bullish | |
| $49.82 | $109.98 | $232.42 | +757% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $8.86 | $12.83 | $16.36 | +0.00% |
| September 2026 | $11.89 | $14.23 | $17.62 | +10.87% |
| October 2026 | $11.85 | $14.31 | $17.98 | +0.60% |
| November 2026 | $12.21 | $14.87 | $18.90 | +3.90% |
| December 2026 | $13.24 | $16.24 | $20.87 | +9.24% |
Click any year to see its month-by-month BBNX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Beta Bionics, Inc.'s 2026 outlook centres on $12.83, within a $8.86 to $20.87 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, BBNX could reach as high as $27.50, with a base case around $19.79 and support toward $15.23 — roughly +54% from $12.83. Momentum favours further upside here.
Expect BBNX to range from $16.42 to $32.46 through 2028. The $22.23 average target implies a +73% move from current prices. That is up +12% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The BBNX price prediction for 2029 points to an average of $23.26 (low $16.61, high $35.28) — a potential gain of +81% on today's $12.83. Momentum favours further upside here.
In 2030, BBNX is projected to trade between $16.81 and $37.99, averaging $24.27 — a potential gain of +89% from today's $12.83. That is up +4% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Beta Bionics, Inc.'s 2031 outlook centres on $25.64, within a $17.27 to $41.25 range. That is up +6% on the projected 2030 average. That marks a +100% change versus current levels. Momentum favours further upside here.
By 2032, BBNX could reach as high as $45.36, with a base case around $27.51 and support toward $18.05 — roughly +114% from $12.83. Buyers look set to stay in control over this stretch.
Expect BBNX to range from $23.02 to $60.61 through 2033. The $35.96 average target implies a +180% move from current prices. That is up +31% on the projected 2032 average. Momentum favours further upside here.
The BBNX price prediction for 2034 points to an average of $41.17 (low $25.74, high $70.81) — a potential gain of +221% on today's $12.83. Buyers look set to stay in control over this stretch.
In 2035, BBNX is projected to trade between $25.91 and $74.30, averaging $42.41 — a potential gain of +231% from today's $12.83. That is up +3% on the projected 2034 average. Momentum favours further upside here.
Beta Bionics, Inc.'s 2040 outlook centres on $61.85, within a $33.99 to $117.06 range. That is up +46% on the projected 2035 average. That marks a +382% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, BBNX could reach as high as $232.42, with a base case around $109.98 and support toward $49.82 — roughly +757% from $12.83. Momentum favours further upside here.
Investing $1,000 in BBNX today (≈ 77.942323 BBNX) could be worth
$8,572.44
+$7,572.44 (+757%) by 2050 · US Dollar
Based on the average projected BBNX price of $109.98 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BBNXwould be worth at today's price.
$1,000 invested in BBNX on Jul 31, 2025 (≈ 59.559258 BBNX) would be worth
$764.15
-$235.85 (-23.6%) today · 0.76× · US Dollar
Based on a BBNX entry price of $16.79 vs. today's $12.83.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $15.85 | $809.46 | -19.1% |
| 1 month ago | $16.7 | $768.26 | -23.2% |
| 3 months ago | $10.29 | $1,246.84 | +24.7% |
| 6 months ago | $13.7 | $936.5 | -6.4% |
| 1 year ago | $16.79 | $764.15 | -23.6% |
| All time (1.5y) ago | $23.63 | $542.95 | -45.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BBNX forecast.
Our base-case forecast reaches $26.00 around 2032.
Implied market cap at $26.00: $1.17B
The multi-year forecast depicts a bullish path, with 2027 avg $19.79, 2028 $22.23, 2029 $23.26, and 2030 $24.27 as the averages begin a steady ascent toward later years.
Beyond 2030, the forecast shows 2033 avg $35.96, 2040 avg $61.85, and 2050 avg $109.98, underscoring meaningful longer-term upside. ROI figures accompany these levels, rising from 54.3% in 2027 to 89.1% in 2030, 382.1% in 2040, and 757.2% in 2050, with sentiment labeled as BULLISH across the horizon.
Drivers cited in the data include ongoing development of automated insulin delivery devices and existing collaboration agreements with Xeris and Abbott Diabetes Care, which may influence adoption and form factors. Risks include high volatility and uncertainty inherent in long-term price forecasts, as these are estimates and not guarantees of future results.
Tap a question to reveal the answer.
According to the forecast, BBNX could average $24.27 in 2030 (min $16.81, max $37.99) with an estimated ROI of 89.1% and a bullish sentiment.
The forecast shows a bullish path from 2027 onward, with 2027 avg $19.79, 2028 $22.23, 2029 $23.26, and 2030 $24.27, and a long-run avg of $109.98 in 2050 with 757.2% ROI. These are estimates, not guarantees.
The 2040 forecast shows an avg of $61.85, which would exceed $50, while 2033 is $35.96 and 2040 is $61.85. These figures suggest the $50 level could be approached by 2040 according to the given path.
RSI14 is 30, the 30-day range is $10.00–$16.47, the SMA50 is $14.79, the SMA200 is $17.57, with support at $12.83 and resistance at $17.82.
Current price is $12.83 and market cap is $577.22M.
Beta Bionics, Inc. Community Discussion
0Share your Beta Bionics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.